PMID: 9438681Jan 23, 1998Paper

Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers

Psychopharmacology
M E ReithQ S Yan

Abstract

Extracellular levels of dopamine (DA), serotonin (5-HT), and norepinephrine (NE) were measured by microdialysis in conscious rats equipped with dual probes, one in the ventral tegmental area (VTA) and another one in the contralateral nucleus accumbens (NACC). Dialysate content of all amines in both regions was essentially abolished by local infusion of tetrodotoxin (1 microM) or Ca2+-free buffer. Injection of the selective DA uptake blocker GBR 12935 (15 mg/kg i.p.) increased DA, as well as NE and, to a lesser extent, 5-HT in the VTA; it increased DA more than 5-HT in the NACC. The selective NE uptake blocker desipramine (10 mg/kg i.p.) increased NE but also 5-HT in the VTA and NACC; the DA level was persistently enhanced in the VTA, whereas in the NACC it initially rose and then fell below baseline value. The selective 5-HT uptake blocker citalopram (15 mg/kg i.p.) was generally more effective in elevating dialysate level of 5-HT than that of other amines in both regions. Cocaine (20 mg/kg i.p.) was non-selective in enhancing all three amines in both regions. There is considerable crosstalk between monoamine systems occurring upon systemic administration of uptake blockers, and the VTA and NACC are notably different in the tim...Continue Reading

Citations

Dec 4, 2012·Journal of Molecular Neuroscience : MN·Bermary Santos-VeraCarlos A Jiménez-Rivera
Jul 1, 2011·Molecular Neurobiology·Vishnudutt PurohitDavid Shurtleff
Jun 1, 2005·Pharmacology, Biochemistry, and Behavior·Jonathon C Arnold
Oct 26, 2002·European Journal of Pharmacology·Paul N DeslandesRobert D E Sewell
Jun 5, 2003·European Journal of Pharmacology·Zsolt SelmeczyE Sylvester Vizi
Dec 14, 2002·Brain Research. Developmental Brain Research·Kay L KestersonRobert W Rhoades
Oct 16, 2002·Trends in Pharmacological Sciences·Raul R GainetdinovMarc G Caron
Jan 9, 2001·Brain Research. Molecular Brain Research·A K HalladayR Zhou
Jan 5, 1999·Neurochemistry International·I SzirákiA Lajtha
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Patricia A BroderickYueping Zhou
Dec 15, 2000·Progress in Neurobiology·T M Tzschentke
Jul 9, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John R MantschHolly Caretta
Feb 3, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stanislav KoulchitskyVincent Seutin
Jan 25, 2003·The European Journal of Neuroscience·Arthur S P JansenFred J H Tilders
Jan 26, 2000·Journal of Neurochemistry·S Rahman, W J McBride
Oct 9, 2004·Behavioural Pharmacology·C P MüllerJ P Huston
Nov 9, 2007·Behavioural Pharmacology·Katharine A BrennanSusan Schenk
Mar 3, 2010·Behavioural Pharmacology·Paul L SotoJonathan L Katz
Feb 22, 2005·Genes, Brain, and Behavior·H M KamensT J Phillips
Jul 21, 1998·Annals of the New York Academy of Sciences·A E CalogeroR D'Agata
Apr 10, 2009·The Journal of Pharmacology and Experimental Therapeutics·Katherine L NicholsonAnthony S Basile
Jan 28, 2014·Brain, Behavior, and Immunity·Lee W HutsonDonald T Lysle
Feb 7, 2014·Psychopharmacology·Natalie A Hadad, Lori A Knackstedt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.